Nuvalent, Inc. (NUVL)
Oxford Ledge is still expanding full research coverage of NUVL. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Clinical-stage biopharmaceutical company developing targeted cancer therapies for ROS1 and ALK-positive lung cancer.
SEC filings
- 8-K Shareholder vote results 2026-06-18
- 8-K Entry into material agreement; Regulation FD disclosure; Financial statements and exhibits 2026-06-09
- 10-Q Quarterly financial report (unaudited) 2026-05-07
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-07
- DEF 14A Proxy statement for shareholder vote 2026-04-28
Source: SEC EDGAR.
Annual results
5 years of annual figures for NUVL, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$425.4M | -$5.85 |
| 2024 | — | -$260.8M | -$3.93 |
| 2023 | — | -$126.2M | -$2.17 |
| 2022 | — | -$81.9M | -$1.65 |
| 2021 | — | -$46.3M | -$2.13 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for NUVL. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NUVL in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.